Justyna Kelly

Chief Operating Officer presso POINT Biopharma, Inc. (United States)

39 anni

Consumer Services

Health Technology

Commercial Services

Profilo

Justyna Kelly is currently the VP-Medical Isotope Development & Operations at POINT Biopharma, Inc. She was previously the Chief Operating Officer at POINT Biopharma Global, Inc. from 2021 to 2023.
Ms. Kelly received her undergraduate and graduate degrees from McMaster University.

Posizioni attive di Justyna Kelly

Società	Posizione	Inizio
POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	Chief Operating Officer	-

Tutte le posizioni attive di Justyna Kelly

Precedenti posizioni note di Justyna Kelly

Società	Posizione	Fine
POIT BIOP	Chief Operating Officer	27/12/2023

Vedi nel dettaglio l'esperienza di Justyna Kelly

Formazione di Justyna Kelly

McMaster University

Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Justyna Kelly

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
POIT BIOP	Health Technology

Aziende private	1
POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The private company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	Commercial Services